Super-capacitor energy storage system to recuperate regenerative braking energy in elevator operation of high buildings

In operating phases of elevators, accelerating, braking modes occur frequently, so braking energy recuperation of elevators has contributed considerably to decrease the total electric energy consumption for operating elevators in multi-floor buildings. In this paper, the supercapacitor energy storage system is used to recover regenerative braking energy of elevators when they operate down full-load and up no-load, reducing fluctuation of voltage on DC bus as well. Therefore, super-capacitor energy storage system (SCESS) will be parallel with line utility to recuperate regenerative braking energy in braking phase and support energy for acceleration phase. The surplus energy will be stored in the supercapacitors thanks to a DC-DC converter capable of exchanging energy bidirectionally in buck/boost modes, and designing control strategy including two control loops. Inner loop-current loop: controlling charge/discharge process of supercapacitors by current iL complying with operation characteristic of elevator; Outer loop-voltage loop: managing UDC-link at a fixed value. Simulation results with elevator system of the ten-floor building, Hanoi, Vietnam installed SCESS have been verified on MATLAB Simulink, SimPowerSystem with saving energy level about 30%

A novel method for determining fixed running time in operating electric train tracking optimal speed profile

Tracking the optimal speed profile in electric train operation has been proposed as a potential solution for reducing energy consumption in electric train operation, at no cost to improve infrastructure of existing Metro lines as well. However, the optimal speed profile needs to meet fixed running time. Therefore, this paper focuses on a new method for determining the fixed running time complied with the scheduled timetable when trains track the optimal speed profile. The novel method to ensure the fixed running time is the numerical-analytical one. Calculating accelerating time ta, coasting time tc, braking time tb via values of holding speed vh, braking speed vb of optimal speed profile with the constraint condition: the running time equal to the demand time. The other hands, vh and vb are determined by solving nonlinear equations with constraint conditions. Additionally, changing running time suit for each operation stage of metro lines or lines starting to conduct schedules by the numerical-analytical method is quite easy. Simulation results obtained for two scenarios with data collected from electrified trains of Cat Linh-Ha Dong metro line, Vietnam show that running time complied with scheduled timetables, energy saving by tracking optimal speed profile for the entire route is up to 8.7%, if the running time is one second longer than original time, energy saving is about 11.96%

Speed profile optimization of an electrified train in Cat Linh-Ha Dong metro line based on pontryagin's maximum principle

An urban railway is a complex technical system that consumes large amounts of energy, but this means of transportation still has been obtained more and more popularity in densely populated cities because of its features of high-capacity transportation capability, high speed, security, punctuality, lower emission, reduction of traffic congestion. The improved energy consumption and environment are two of the main objectives for future transportation. Electrified trains can meet these objectives by the recuperation and reuse of regenerative braking energy and by the energy - efficient operation. Two methods are to enhance energy efficiency: one is to improve technology (e.g., using energy storage system, reversible or active substations to recuperate regenerative braking energy, replacing traction electric motors  by energy-efficient traction system as permanent magnet electrical motors; train's mass reduction by lightweight material mass...); the other is to improve operational procedures (e.g. energy efficient driving including: eco-driving; speed profile optimization; Driving Advice System (DAS); Automatic Train Operation (ATO); traffic management optimization...). Among a lot of above solutions for saving energy, which one is suitable for current conditions of metro lines in Vietnam. The paper proposes the optimization method based on Pontryagin's Maximum Principle (PMP) to find the optimal speed profile for electrified train of Cat Linh-Ha Dong metro line, Vietnam in an effort to minimize the train operation energy consumption

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial

Background Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to show if daily oral fluoxetine for 6 months after stroke improves functional outcome in an ethnically diverse population. Methods AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial done in 43 hospital stroke units in Australia (n=29), New Zealand (four), and Vietnam (ten). Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke in the previous 2–15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a persisting neurological deficit that produced a modified Rankin Scale (mRS) score of 1 or more. Patients were randomly assigned 1:1 via a web-based system using a minimisation algorithm to once daily, oral fluoxetine 20 mg capsules or matching placebo for 6 months. Patients, carers, investigators, and outcome assessors were masked to the treatment allocation. The primary outcome was functional status, measured by the mRS, at 6 months. The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for minimisation variables. Primary and safety analyses were done according to the patient's treatment allocation. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000774921. Findings Between Jan 11, 2013, and June 30, 2019, 1280 patients were recruited in Australia (n=532), New Zealand (n=42), and Vietnam (n=706), of whom 642 were randomly assigned to fluoxetine and 638 were randomly assigned to placebo. Mean duration of trial treatment was 167 days (SD 48·1). At 6 months, mRS data were available in 624 (97%) patients in the fluoxetine group and 632 (99%) in the placebo group. The distribution of mRS categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio 0·94, 95% CI 0·76–1·15; p=0·53). Compared with patients in the placebo group, patients in the fluoxetine group had more falls (20 [3%] vs seven [1%]; p=0·018), bone fractures (19 [3%] vs six [1%]; p=0·014), and epileptic seizures (ten [2%] vs two [<1%]; p=0·038) at 6 months. Interpretation Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures. These results do not support the use of fluoxetine to improve functional outcome after stroke

Prevalence and Associated Factors of <i>optrA</i>-Positive-<i>Enterococcus faecalis</i> in Different Reservoirs around Farms in Vietnam

Linezolid is an antibiotic of last resort for the treatment of infections caused by Gram-positive bacteria, including vancomycin-resistant enterococci. Enterococcus faecalis, a member of enterococci, is a significant pathogen in nosocomial infections. E. faecalis resistance to linezolid is frequently related to the presence of optrA, which is often co-carried with fex, phenicol exporter genes, and erm genes encoding macrolide resistance. Therefore, the common use of antibiotics in veterinary might promote the occurrence of optrA in livestock settings. This is a cross-sectional study aiming to investigate the prevalence of optrA positive E. faecalis (OPEfs) in 6 reservoirs in farms in Ha Nam province, Vietnam, and its associated factors and to explore genetic relationships of OPEfs isolates. Among 639 collected samples, the prevalence of OPEfs was highest in flies, 46.8% (51/109), followed by chickens 37.3% (72/193), dogs 33.3% (17/51), humans 18.7% (26/139), wastewater 16.4% (11/67) and pigs 11.3%, (14/80). The total feeding area and total livestock unit of the farm were associated with the presence of OPEfs in chickens, flies, and wastewater. Among 186 OPEfs strains, 86% were resistant to linezolid. The presence of optrA was also related to the resistant phenotype against linezolid and levofloxacin of E. faecalis isolates. Close genotypic relationships identified by Pulsed Field Gel Electrophoresis between OPEfs isolates recovered from flies and other reservoirs including chickens, pigs, dogs, and wastewater suggested the role of flies in the transmission of antibiotic-resistant pathogens. These results provided warnings of linezolid resistance although it is not used in livestock

Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization

Despite their promise, circulating tumor DNA (ctDNA)-based assays for multi-cancer early detection face challenges in test performance, due mostly to the limited abundance of ctDNA and its inherent variability. To address these challenges, published assays to date demanded a very high-depth sequencing, resulting in an elevated price of test. Herein, we developed a multimodal assay called SPOT-MAS (screening for the presence of tumor by methylation and size) to simultaneously profile methylomics, fragmentomics, copy number, and end motifs in a single workflow using targeted and shallow genome-wide sequencing (~0.55×) of cell-free DNA. We applied SPOT-MAS to 738 non-metastatic patients with breast, colorectal, gastric, lung, and liver cancer, and 1550 healthy controls. We then employed machine learning to extract multiple cancer and tissue-specific signatures for detecting and locating cancer. SPOT-MAS successfully detected the five cancer types with a sensitivity of 72.4% at 97.0% specificity. The sensitivities for detecting early-stage cancers were 73.9% and 62.3% for stages I and II, respectively, increasing to 88.3% for non-metastatic stage IIIA. For tumor-of-origin, our assay achieved an accuracy of 0.7. Our study demonstrates comparable performance to other ctDNA-based assays while requiring significantly lower sequencing depth, making it economically feasible for population-wide screening

Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration

Background and Purpose: The AFFINITY trial (Assessment of Fluoxetine in Stroke Recovery) reported that oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and seizures. After trial medication was ceased at 6 months, survivors were followed to 12 months post-randomization. This preplanned secondary analysis aimed to determine any sustained or delayed effects of fluoxetine at 12 months post-randomization. Methods: AFFINITY was a randomized, parallel-group, double-blind, placebo-controlled trial in adults (n=1280) with a clinical diagnosis of stroke in the previous 2 to 15 days and persisting neurological deficit who were recruited at 43 hospital stroke units in Australia (n=29), New Zealand (4), and Vietnam (10) between 2013 and 2019. Participants were randomized to oral fluoxetine 20 mg once daily (n=642) or matching placebo (n=638) for 6 months and followed until 12 months after randomization. The primary outcome was function, measured by the modified Rankin Scale, at 6 months. Secondary outcomes for these analyses included measures of the modified Rankin Scale, mood, cognition, overall health status, fatigue, health-related quality of life, and safety at 12 months. Results: Adherence to trial medication was for a mean 167 (SD 48) days and similar between randomized groups. At 12 months, the distribution of modified Rankin Scale categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio, 0.93 [95% CI, 0.76–1.14]; P =0.46). Compared with placebo, patients allocated fluoxetine had fewer recurrent ischemic strokes (14 [2.18%] versus 29 [4.55%]; P =0.02), and no longer had significantly more falls (27 [4.21%] versus 15 [2.35%]; P =0.08), bone fractures (23 [3.58%] versus 11 [1.72%]; P =0.05), or seizures (11 [1.71%] versus 8 [1.25%]; P =0.64) at 12 months. Conclusions: Fluoxetine 20 mg daily for 6 months after acute stroke had no delayed or sustained effect on functional outcome, falls, bone fractures, or seizures at 12 months poststroke. The lower rate of recurrent ischemic stroke in the fluoxetine group is most likely a chance finding. REGISTRATION: URL: http://www.anzctr.org.au/ ; Unique identifier: ACTRN12611000774921